Diabetic Macular Edema Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Diabetic Macular Edema Clinical Trials Market Report Overview
The Diabetic Macular Edema Clinical Trials market research report provides an overview of Diabetic Macular Edema Clinical trials scenario. This report provides top line data relating to the clinical trials on Diabetic Macular Edema. The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. The report also provides prominent drugs for in-progress trials (based on number of ongoing trials).
Key Regions |
|
Key Countries |
|
Key Sponsor Types |
|
Leading Sponsors |
|
Enquire & Decide
|
Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
Diabetic Macular Edema Clinical Trials Market Segmentation by Regions and Countries
The key regions in the Diabetic Macular Edema clinical trials market are Asia-Pacific, Europe, North America, the Middle East & Africa, and South & Central America. The Asia-Pacific region dominates the market and is followed by the North America and Europe.
In a country-wise analysis, as of May 2023, the US has the highest number of Diabetic Macular Edema clinical trials, followed by Japan, China, Germany, the United Kingdom, India, Canada, Spain, Iran, and Italy
G7 countries: Among the G7 (United States, United Kingdom, Germany, France, Italy, Canada and Japan) countries, Italy has the highest proportion of Diabetic Macular Edema to Metabolic Disorders clinical trials as of May 2023.
E7 countries: Among the E7 (Brazil, Russia, India, China, Mexico, Turkey and Indonesia) countries, Turkey has the highest proportion of Diabetic Macular Edema to Metabolic Disorders clinical trials as of May 2023.
Diabetic Macular Edema Clinical Trials Analysis by Regions, 2023 (%)
For more regional insights into the Diabetic Macular Edema clinical trials market, download a free report sample
Diabetic Macular Edema Clinical Trials Market Segmentation by Sponsor Types
The key sponsor types in the Diabetic Macular Edema clinical trials market are institution, company, and the government. Out of them, the institution sponsor type dominates the market, followed by company.
Diabetic Macular Edema Clinical Trials Market Analysis by Sponsor Types, 2023 (%)
For more sponsor type insights into the Diabetic Macular Edema clinical trials market, download a free report sample
Diabetic Macular Edema Clinical Trials Market - Competitive Landscape
The leading sponsors in the Diabetic Macular Edema clinical trials market are Novartis AG, F. Hoffmann-La Roche Ltd, Bayer AG, AbbVie Inc, Regeneron Pharmaceuticals Inc, Alimera Sciences Inc, Pfizer Inc, Santen Pharmaceutical Co Ltd, Oxurion NV, and Bausch Health Companies Inc. Novartis AG led the diabetic macular edema clinical trials market in 2023.
Diabetic Macular Edema Clinical Trials Market Analysis by Sponsors, 2023 (%)
To know more about the leading players in the Diabetic Macular Edema clinical trials market, download a free report sample
Segments Covered in the Report
Diabetic Macular Edema Clinical Trials Regional Outlook (2023)
- Asia-Pacific
- North America
- Europe
- Middle East & Africa
- South & Central America
Diabetic Macular Edema Clinical Trials Country Outlook (2023)
- The US
- Japan
- China
- Germany
- The United Kingdom
- India
- Canada
- Spain
- Iran
- Italy
Diabetic Macular Edema Clinical Trials Sponsor Type Outlook (2023)
- Institution
- Company
- Government
Scope
- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months
Reasons to Buy
- Assists in formulating key business strategies with regards to investment.
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost.
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities.
- Supports understanding of trials count and enrollment trends by country in global therapeutics market.
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials.
- Facilitates clinical trial assessment of the indication on a global, regional and country level.
F. Hoffmann-La Roche Ltd
Bayer AG
AbbVie Inc
Regeneron Pharmaceuticals Inc
Alimera Sciences Inc
Pfizer Inc
Santen Pharmaceutical Co Ltd
Oxurion NV
Bausch Health Companies Inc
Table of Contents
Frequently asked questions
-
Which is the leading region in the Diabetic Macular Edema clinical trials market?
Asia-Pacific is the leading region in the Diabetic Macular Edema clinical trials market as of May 2023.
-
Which is the leading country in the Diabetic Macular Edema clinical trials market?
The US is the leading country in the Diabetic Macular Edema clinical trials market as of May 2023.
-
Which is the leading sponsor type in the Diabetic Macular Edema clinical trials market?
Institution is the leading sponsor type in the Diabetic Macular Edema clinical trials market as of May 2023.
-
Who are the leading sponsors in the Diabetic Macular Edema clinical trials market?
The leading sponsors in the Diabetic Macular Edema clinical trials market are Novartis AG, F. Hoffmann-La Roche Ltd, Bayer AG, AbbVie Inc, Regeneron Pharmaceuticals Inc, Alimera Sciences Inc, Pfizer Inc, Santen Pharmaceutical Co Ltd, Oxurion NV, and Bausch Health Companies Inc
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Related reports
View more Diabetic Macular Edema reports

